EyePoint Pharmaceuticals Inc (EYPT)
11.70
-0.36
(-2.99%)
USD |
NASDAQ |
Nov 04, 16:00
11.50
-0.20
(-1.71%)
After-Hours: 06:39
EyePoint Pharmaceuticals Free Cash Flow: -94.36M for June 30, 2024
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2024 | -94.36M |
| March 31, 2024 | -16.65M |
| December 31, 2023 | -1.608M |
| September 30, 2023 | 9.211M |
| June 30, 2023 | 11.80M |
| March 31, 2023 | -64.17M |
| December 31, 2022 | -67.16M |
| September 30, 2022 | -70.65M |
| June 30, 2022 | -64.23M |
| March 31, 2022 | -55.46M |
| December 31, 2021 | -50.25M |
| September 30, 2021 | -27.88M |
| June 30, 2021 | -18.96M |
| March 31, 2021 | -13.54M |
| December 31, 2020 | -14.80M |
| September 30, 2020 | -31.99M |
| June 30, 2020 | -47.77M |
| March 31, 2020 | -59.76M |
| December 31, 2019 | -56.91M |
| September 30, 2019 | -57.30M |
| June 30, 2019 | -48.65M |
| March 31, 2019 | -36.34M |
| September 30, 2018 | -27.86M |
| June 30, 2018 | -22.02M |
| March 31, 2018 | -20.47M |
| Date | Value |
|---|---|
| December 31, 2017 | -20.21M |
| September 30, 2017 | -20.18M |
| June 30, 2017 | -20.64M |
| March 31, 2017 | -20.45M |
| December 31, 2016 | -20.23M |
| September 30, 2016 | -18.41M |
| June 30, 2016 | -16.43M |
| March 31, 2016 | -15.13M |
| December 31, 2015 | -14.80M |
| September 30, 2015 | 9.632M |
| June 30, 2015 | 10.14M |
| March 31, 2015 | 10.27M |
| December 31, 2014 | 12.36M |
| September 30, 2014 | -11.13M |
| June 30, 2014 | -10.92M |
| March 31, 2014 | -11.36M |
| December 31, 2013 | -11.43M |
| September 30, 2013 | -10.97M |
| June 30, 2013 | -8.813M |
| March 31, 2013 | -7.258M |
| December 31, 2012 | -7.445M |
| September 30, 2012 | -8.15M |
| June 30, 2012 | -9.406M |
| March 31, 2012 | -6.382M |
| December 31, 2011 | -5.842M |
Free Cash Flow Range, Past 5 Years
-94.36M
Minimum
Jun 2024
11.80M
Maximum
Jun 2023
-38.69M
Average
-47.77M
Median
Jun 2020
Free Cash Flow Benchmarks
| Cassava Sciences Inc | -86.31M |
| Adverum Biotechnologies Inc | -89.12M |
| Regenxbio Inc | -194.72M |
| Editas Medicine Inc | -171.54M |
| Apellis Pharmaceuticals Inc | -408.81M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -20.18M |
| Cash from Investing (Quarterly) | -160.40M |
| Cash from Financing (Quarterly) | 0.329M |
| Free Cash Flow Per Share (Quarterly) | -0.3962 |
| Free Cash Flow to Equity (Quarterly) | -21.08M |
| Free Cash Flow Yield | -17.28% |